Portola Pharmaceuticals (South San Francisco, CA) a clinical-stage small moelcule company focused on acute and chronic cardiovascular and autoimmune and inflammatory diseases, closed an $89M Series E financing. Participants included Temasek, Eastern Capital Limited, D.E. Shaw, Adage Capital Management, BBT Capital Management, Janus Capital Group and Pac-Link BioVentures.

arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.

Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical company focused on allergy and autoimmune conditions, closed a $98M Series D financing. Participants include Imperial Innovations and Invesco Perpetual.

Symphogen (Denmark) a clinical-stage developer of recombinant polyclonal antibodies for the treatment of cancer and infectious and autoimmune diseases, closed a $135.4M Series F financing. Participants include Essex Woodlands Health Ventures, Novo, and Pensionskassernes Administration.

Femta Pharmaceuticals (San Diego, CA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for the treatment of inflammation and autoimmune disease, closed a $2.2M Series A financing. Participants include Latterell Venture Partners.

DecImmune Therapeutics (Boston, MA) a development-stage biopharmaceutica focused on inflammation and autoimmunity, closed a $1M Series A financing. Participants include Astellas Venture Management, Amgen Ventures and HealthCare Ventures.

Complix (Belgium) a preclinical-stage biopharmaceutical focused on alphabody therapeutics for autoimmune and infectious diseases, closed a $6.2M Series A financing. Participants include Vesalius Biocapital, LRM and CRP Santé.

Flexion Therapeutics (Woburn, MA) a clinical-stage biopharma focused on autoimmune disease, ulcerative colitis and tinnitus, closed a $9M Series A financing, bringing the total round to $42M. Participants include Pfizer Venture Investments, Versant Ventures, 5AM Ventures and Sofinnova Ventures.

arGEN-X (Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform with potential indications in autoimmunity, oncology and bone disease, closed a $4.5M Series A financing, bring total round proceeds to $18.3M. Participants have included Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund, [...]

CalciMedica (La Jolla, CA) a preclinical-stage small molecule company focused on autoimmune and inflammatory via the inhibition of calcium release-activated calcium (CRAC) channels, closed a $5M Series C financing, bringing the total round up to $9M. Participants include Biogen Idec, Sanderling Ventures and SR One.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Zyngenia (Rockville, MD) a pre-clinical stage biotherapeutics company focused on multi-specific antibodies for oncology and autoimmune disorders, closed a $10M Series A financing. Particpants include New Enterprise Associates.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Receptos (San Diego, CA) a preclinical stage biopharmaceutical company focused on structural biolog GPCR approaches targeting autoimmune disease, closed a $25M Series A financing. Participants include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Virdante Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on increasing potency of plasma-derived intravenous immune globulin for the treatment of inflammation and autoimmune disease, closed a $30M Series A financing. Participants include Thomas, McNerney & Partners, Osage Partners, Clarus Ventures, Venrock, MedImmune Ventures and Biogen Idec New Ventures.